Contact this trialFirst, we need to learn more about you.
MEK Inhibitor
Avutometinib + Defactinib for Ovarian Cancer
Recruiting2 awardsPhase 3
New York, New York
This trial will test if a drug combo is safer and more effective to treat a specific type of ovarian cancer than existing treatments.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service